AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02044094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydromorphone
Description: Hydromorphone IM challenges are administered during the screening period (days -17 to -15), on days -3 to -1 during the buprenorphine and naloxone (SUBOXONE sublingual film) stabilization period, and weekly during the 12-week treatment period after administration of RBP-6000. Each challenge consists of 3 days during which participants are randomly administered 0 mg (placebo), 6 mg and 18 mg hydromorphone via intramuscular (IM) injection daily in varying blinded sequences.~Additionally, hydromorphone can also be earned during the afternoon Reinforcing effects tasks sessions up to the same randomized dose received in the hydromorphone challenge that morning (or money can be chosen).
Study NCT02044094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo for hydromorphone administered via intramuscular injection during each challenge.
Study NCT00649714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide Capsules 100 mg
Description: 100mg, single dose fed
Study NCT00649714 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zonegran® Capsules 100 mg
Description: 100mg, single dose fed
Study NCT01393574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 3 mg for body weight \<40kg, 6 mg for body weight >40kg, once a day 30-60 minutes before sleep
Study NCT01393574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: Drug formulary and dose will be decided by the treating neurologist from the available options in Israel (as would be given if not participating in the trial)
Study NCT02584972 — intervention group
Intervention type: OTHER
Intervention: no intervention required
Description: no intervention required
Study NCT02071472 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DP medication reconciliation
Study NCT03371095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Use of infliximab instead of cyclophosphamide
Study NCT03371095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Use of cyclophosphamide
Study NCT03233009 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Daily Defense Serum A
Description: Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
Study NCT03233009 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Daily Defense Serum C
Description: Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
Study NCT03233009 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Daily Defense Serum G
Description: Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
Study NCT03197623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LLP2A-ALENDRONATE
Description: A small molecule, LLP2A-Ale that directs endogenous mesenchymal stem cells (MSCs), the cells that have the potential to grow bone tissue, to the bone surface to form new bone. Single administration of LLP2A-Ale given intravenously over 120 minutes.
Study NCT03197623 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, one time single administration given intravenously over 120 minutes.
Study NCT03233009 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Daily Defense Serum N
Description: Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
Study NCT03233009 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Saline Solution Sodium Chloride
Description: Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
Study NCT01961778 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radio-Frequency Ablation
Study NCT01961778 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy
Study NCT01744275 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3 fatty acids
Study NCT01744275 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: corn oil
Description: Placebo
Study NCT02706015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefaliv® & Placebo
Description: 02 tablet of Cefaliv® + 02 tablet of comparator placebo, VO, after the beging of migraine with with mild to moderate pain
Study NCT02706015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neosaldina® & Placebo
Description: 02 tablets of Neosaldina® + 02 tablet of comparator placebo, VO, after the beging of migraine with with mild to moderate pain
Study NCT02029729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omaveloxolone
Study NCT04435431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesdopetam
Description: Oral use
Study NCT01729273 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet and Exercise Intervention
Description: Remote Dietary and Exercise Intervention Program
Study NCT02476019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS-FGFR4RX
Description: ISIS-FGFR4RX administered subcutaneously
Study NCT02476019 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered subcutaneously
Study NCT00221338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: This is a Double blind, placebo-controlled experimental study in which gabapentin adjusted for renal clearance (or placebo) is given preoperatively and also the first three postoperative days
Study NCT00221338 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gabapentin
Description: This is a Double blind, placebo-controlled experimental study in which gabapentin adjusted for renal clearance (or placebo) is given preoperatively and also the first three postoperative days
Study NCT04825392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX008
Description: Patients will receive HX008 3mg/kg by intravenous (IV) infusion on Day 1, every 3 weeks (Q3W), till progressed disease or withdrawal.
Study NCT00286104 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotics-impregnated ventricular catheter (Bactiseal®)
Description: Antibiotics-impregnated ventricular catheter (Rifampicin- and Clindamycin-impregnated)
Study NCT00286104 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Plain ventricular catheter (Codman EDS II/III)
Description: Plain ventricular catheter
Study NCT04756947 — intervention group
Intervention type: PROCEDURE
Intervention: surgical treatment according to standard indication criteria
Description: internal fixation according to standard indication criteria
Study NCT04756947 — intervention group
Intervention type: PROCEDURE
Intervention: conservative treatment according to standard indication criteria
Description: conservative therapy according to standard indication criteria
Study NCT04596150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX-072
Description: Intravenous administration of the CX-072 of 1200 mg administered every 3 weeks (Q3W)
Study NCT02255461 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT02255461 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00203229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lamotrigine
Description: The intervention type is 'drug' and this arm is a placebo pill created and supplied by the manufacturers of lamotrigine (Lamictal). This drug is an anti-seizure medication.
Study NCT00203229 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The intervention type is 'drug' and this arm is a placebo pill created and supplied by the manufacturers of lamotrigine (Lamictal) to be exact replicas of the actual drug being studied. The placebo arm is titrated in the exact same manor as the active drug arm.
Study NCT03790059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H101
Description: Intraoperative injection of H101 can improve the efficacy of RFA in hepatocellular carcinoma.
Study NCT03790059 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: RFA
Description: Treat the samll HCC with the RFA.
Study NCT03790059 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RFA
Description: Treat the samll HCC with the RFA.
Study NCT00971139 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Access to an OPPC service
Description: Access to an Internet-based messaging system where patients can ask questions and receive advice and support from care providers at the hospital and social counsellors
Study NCT01496469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Febuxostat 80 mg, tablets, orally, once daily for up to 6 weeks
Study NCT01496469 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Febuxostat placebo-matching tablets, orally, once daily for up to 6 weeks.
Study NCT01624116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acarbose
Description: Tab.Acarbose 50mg BD for one day in addition to existing medication to 10% of patients in each treatment arm.
Study NCT01624116 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet and lifestyle
Description: Patients would follow a 1200 KCal Ramadan diet plan, and exercise for 30 minutes per day
Study NCT01624116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Patients on metformin monotherapy prior to Ramadan will continue on it, in the same dose
Study NCT01624116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin/ Glimepride
Description: Metformin 500mg and Glimepride 1mg in a combination tablet. Dosage frequency BD
Study NCT01624116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin/Sitagliptin
Description: Metformin 500 and sitagliptin 50mg in a combination tablet,dosage frequency BD.
Study NCT03686293 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized breakfast
Description: One tablet of paracetamol (500 mg) and a glass of water (150 mL) is consumed followed by a breakfast consisting of white bread, butter, jam, and juice (300 mL) and
Study NCT00082407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 48 weeks
Study NCT00082407 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart
Description: subcutaneous injection, twice daily; titration to target blood glucose level
Study NCT00091091 — intervention group
Intervention type: OTHER
Intervention: medical chart review
Study NCT04001569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8186 in combination with paclitaxel
Description: Phase 1b is planned for a 4-stage dose level and the traditional 3+3 design is applied. The RP2D will be determined based on the MTD and toxicity profiles.~In phase 2 part, RP2D from the phase 1b part will be applied.~* AZD8186 ( )mg po bid, 5 days on, 2 days off~* Paclitaxel ( )mg/m² on D1,8,15 every 4 weeks
Study NCT00091091 — intervention group
Intervention type: OTHER
Intervention: questionnaire administration
Study NCT00091091 — intervention group
Intervention type: PROCEDURE
Intervention: management of therapy complications
Study NCT03172312 — intervention group
Intervention type: PROCEDURE
Intervention: Different range of thyroid surgery
Description: Observe and record parathyroid status during thyroid surgery
Study NCT03676244 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: immediate implant in defected anterior maxillary esthetic zone
Description: Patients indicated for immediate implant placement with presence of partial or complete loss (type 2 sockets) of labial bone plate.~Use of GBR (mix of autogenous bone graft and xenograft in combination to absorbable collagen membrane) and healing abutment at the same time of extraction then place implant palatally engaging the side walls of the socket, leaving a buccal gap.~construct custom two-piece screw retained healing abutment then remove custom healing abutment and fit and place the collagen membrane for GBR , the membrane should cover the defect 2 mm circumferentially and extend to the level of free gingival margin, Place bone graft material buccal to the implant surface ,replace custom healing abutment.
Study NCT04057807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPS
Description: LPS (0.4 ng/kg)
Study NCT00797277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IM olanzapine
Description: 10mg olanzapine IM
Study NCT00797277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IM haloperidol plus lorazepam
Description: IM 5 mg haloperidol plus IM 2 mg lorazepam
Study NCT03477396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitor
Description: Aromatase inhibitor per treating investigator's discretion
Study NCT03477396 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03477396 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic Study
Description: Correlative studies
Study NCT03477396 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04435431 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral use
Study NCT03605758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin
Description: Ivermectin is an anti-parasitic
Study NCT01471600 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: group drink
Description: group glucose drink : 200 ml of fruit juice without pulp, ± 200ml coffee or tea, 2 at 4 hours before induction of anaesthesia
Study NCT03477396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Given PO
Study NCT04259125 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw
Description: Evaluation of plasma inflammatory markers including cytokines and micro-RNA.
Study NCT04259125 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Regarding epilepsy and development.
Study NCT03384368 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fractured level screws-distraction
Description: four pedicle screws were implanted into the upper vertebra and the lower vertebral body of the fractured vertebra. Then, immediate reduction and decompression were achieved by applying distraction of rod. Finally, two additional screws were introduced at fracture level
Study NCT03384368 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: fractured level screws-distraction
Description: four pedicle screws were implanted into the upper vertebra and the lower vertebral body of the fractured vertebra. Then, immediate reduction and decompression were achieved by applying distraction of rod. Finally, two additional screws were introduced at fracture level
Study NCT03212963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Halobetasol Topical Lotion
Description: Halobetasol Lotion 0.05%, applied twice daily in subjects aged 12 to 16 years 11 months with stable plaque psoriasis.
Study NCT02084550 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vaminolac
Description: Vaminolac with an amino acid content corresponding humane breast milk.
Study NCT02084550 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Intravenous isotonic saline with a sodium chloride content of 9mg/ml.
Study NCT04577469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maldox tablets
Description: 500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
Study NCT04577469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maldox tablets
Description: 500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
Study NCT04577469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-COSPE® tablets
Description: 500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
Study NCT02129439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB012
Description: The treatment phase lasts 28 consecutive days. The IMP will be administered for the first time at the study site in the morning on Day 1 (IMP administration training by study site staff). The final administration will be performed at the study site in the morning of Day 28. On all other treatment days (Day 2 to Day 27), the IMP will be self-administered by the subject at home.~SB012 will be available in this clinical trial in a concentration of 7.5mg/ml hgd40 in 30ml PBS (Maximum daily dose: 225mg)~The IMP is formulated as an enema and will be administered in this clinical trial by the rectal route. The enema is a ready-for-use preparation. No further preparation steps are required.~No modifications are permitted to the dosing regimen except for premature study discontinuation.
Study NCT04577469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-COSPE® tablets
Description: 500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
Study NCT02123849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Given PO
Study NCT02123849 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02123849 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given PO
Study NCT01321801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Preoperative administration of pregabalin 600mg
Study NCT03262168 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise Programme
Description: Complete background demographics, Sniff Nasal Inspiratory Pressure (study group one only), grip strength, muscle strength, PHQ-9 and GAD-7 questionnaires.
Study NCT03336294 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: SRM P31
Description: All the volunteers involved in the CAMUS study will perform during the SRM P31 a quadricipital physical task at 70% 1-RM.
Study NCT01321801 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Preoperative administration of a matching placebo
Study NCT02129439 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intervention of placebo-treated subjects does not vary to SB012-treated subjects.~The treatment phase lasts 28 consecutive days. Placebo will be administered for the first time at the study site in the morning on Day 1 (Administration training by study site staff). The final administration will be performed at the study site in the morning of Day 28. On all other treatment days (Day 2 to Day 27), the IMP/Placebo will be self-administered by the subject at home. Placebo will be administered with a volume of 30ml.~The IMP/Placebo is formulated as an enema (plastic rectal tube) and will be administered in this clinical trial by the rectal route. The enema is a ready-for-use preparation. No further preparation steps are required.
Study NCT04250506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daridorexant
Description: Daridorexant (ACT-541468) administered as film-coated tablets for oral use.
Study NCT04250506 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered as tablets for oral use.
Study NCT04250506 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Moxifloxacin administered as film-coated tablets for oral use.
Study NCT03184467 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline 0.9%
Description: Normal saline 0.9% is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.
Study NCT03184467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GV1001 0.56 mg
Description: GV1001 0.56 mg is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.
Study NCT03184467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GV1001 1.12 mg
Description: GV1001 1.12 mg is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.
Study NCT01330758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD8931
Description: 40 mg AZD8931 wet granulation tablet formulation
Study NCT04122339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAX-10181
Description: Part 1: Dose escalation, MAX-10181 once or twice daily with dose modifications based on tolerability criteria.~Part 2: Dose expansion, Recommended doses from Part 1.
Study NCT04411030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX660
Description: Form: capsule; Route of administration: oral
Study NCT04411030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Form: syrup; Route of administration: oral